Stock Events

Stock Events

Cotinga Pharmaceuticals

0

0

+€0.00+0% 00:00 Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Amgen is a biotechnology firm developing novel therapies in areas overlapping with Cotinga's focus on cancer treatments.

Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company with a strong portfolio in oncology, competing in the cancer treatment space.

Merck is known for its extensive research and development in oncology, directly competing with Cotinga's cancer therapies.

Pfizer operates in various therapeutic areas including oncology, making it a direct competitor in cancer drug development.

Eli Lilly and Company has a significant focus on cancer research and drug development, aligning as a competitor in the oncology sector.

Gilead Sciences

Gilead Sciences is involved in the development of oncology treatments, competing with Cotinga Pharmaceuticals in the cancer therapy market.

AbbVie has a growing presence in oncology through both research and strategic acquisitions, positioning it as a competitor.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals focuses on innovative biopharmaceuticals, including cancer treatments, competing in the same therapeutic area.

AstraZeneca has a strong pipeline in oncology, directly competing with Cotinga Pharmaceuticals in developing cancer therapies.

Novartis is a global healthcare company with a robust focus on oncology, making it a key competitor in cancer drug development.

About

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

Show more...

CEO

Ms. Alison D. Silva MA, MS

Country

Canada

ISIN

CA22164W1059

Listings

0 Comments

Share your thoughts

FAQ

What is Cotinga Pharmaceuticals stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Cotinga Pharmaceuticals stocks are traded under the ticker A8V1.STU.

In which sector is Cotinga Pharmaceuticals located?▼

Cotinga Pharmaceuticals operates in the Health & Wellness sector.

When did Cotinga Pharmaceuticals complete a stock split?▼

Cotinga Pharmaceuticals has not had any recent stock splits.

Where is Cotinga Pharmaceuticals headquartered?▼

Cotinga Pharmaceuticals is headquartered in Toronto, Canada.